Compare UTZ & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTZ | CGEM |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 912.7M | 794.7M |
| IPO Year | 2018 | 2020 |
| Metric | UTZ | CGEM |
|---|---|---|
| Price | $7.69 | $14.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $13.00 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 1.8M | 696.1K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,438,800,000.00 | N/A |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | $1.52 | $79.85 |
| P/E Ratio | $772.00 | ★ N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $7.12 | $5.68 |
| 52 Week High | $14.67 | $16.74 |
| Indicator | UTZ | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 55.13 |
| Support Level | $7.19 | $11.43 |
| Resistance Level | $10.74 | $16.74 |
| Average True Range (ATR) | 0.30 | 0.87 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 63.69 | 80.91 |
Utz Brands Inc is a manufacturer of branded salty snacks. It produces a broad offering of salty snacks, including potato chips, tortilla chips, pretzels, cheese snacks, pork skins, pub/party mixes, and other snacks. Its iconic portfolio of authentic, craft, and better-for-you (BFY) brands, which includes Utz, Zapp's, On The Border, Golden Flake, and Boulder Canyon, among others, enjoys household penetration in the United States, where its products can be found in approximately half of U.S. household. The company operates in eight manufacturing facilities with a broad range of capabilities, and its products are distributed nationally to grocery, mass, club, convenience, drug, e-commerce and other retailers through direct shipments, distributors, and approximately 2,500 DSD routes.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.